Business News

Merck Completes Acquisition of Themis

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The U.S. Federal Trade Commission has granted early termination of the waiting period …

Read More »

Alpine Immune Sciences and AbbVie Enter Option and License Agreement for Development and Commercialization of ALPN-101

SEATTLE & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, and AbbVie Inc. (NYSE: ABBV), a research-based global biopharmaceutical company, today announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual …

Read More »

ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring to Clinical Research

BOULDER, Colo., June 18, 2020 /PRNewswire/ — ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy. PCM provides tumor-informed longitudinal …

Read More »

Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers. Based in the Netherlands, BlueBee has developed a regulatory compliant, secure …

Read More »

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron

LEIDEN, The Netherlands, June 17, 2020 /PRNewswire/ — ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, today announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo® (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In …

Read More »

Takeda and Neurocrine Partner to Develop and Commercialize Potential Therapies for Psychiatric Disorders

SAN DIEGO & OSAKA, Japan–(BUSINESS WIRE)–Neurocrine Biosciences, Inc. (Nasdaq:NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for …

Read More »

Magenta Therapeutics and Beam Therapeutics Collaborate to Evaluate Targeted Antibody-Drug Conjugate MGTA-117 as Conditioning Regimen for Base Editing Therapies

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted ADC for conditioning of patients with sickle cell disease and beta-thalassemia receiving Beam’s base editing therapies. Beam is pursuing two differentiated base editing …

Read More »

Foundation Medicine Acquires Lexent Bio to Accelerate Liquid Biopsy R&D and Advance Cancer Care

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., today announced that it has completed the acquisition of Lexent Bio, Inc., a precision oncology company located in California, developing novel multiomics liquid biopsy platforms to advance cancer care. This acquisition will accelerate Foundation Medicine’s research and development strategy and expand its existing liquid biopsy …

Read More »

Sobi and Selecta Enter Licensing Agreement for SEL-212, a Phase 3-Ready Novel Treatment for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., June 11, 2020 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced that the companies have entered into a strategic licensing agreement for the product candidate SEL-212. SEL-212 is a combination of Selecta’s tolerogenic ImmTOR immune tolerance platform and …

Read More »

Novo Nordisk to Acquire Corvidia Therapeutics for $725 Million to Expand its Presence in Cardiovascular Disease

Bagsværd, Denmark, 11 June 2020 – Novo Nordisk A/S today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Corvidia Therapeutics’ lead candidate, ziltivekimab, a fully human monoclonal …

Read More »